INTERPACE BIOSCIENCES, INC. (IDXG) Form 10-Q — May 12, 2026
Interpace Biosciences, Inc. reported a 22% decrease in revenue to $9.0 million for the quarter ended March 31, 2026, compared to $11.5 million in the same period of 2025. This decline is primarily attributed to the loss of reimbursement for the PancraGEN® test, which was discontinued in May 2025. The company's net income for the quarter was $0.721 million, a significant decrease from $1.647 million in the same period of 2025.
Key figures
- Eps
- 0.03
- Eps Beat
- 0
- Revenue
- 9032
- Net Income
- 721
- Total Debt
- 5730
- Debt Amount
- 0
- Total Assets
- 33409
- Cash Position
- 2647
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 27700904
Price after filing
1 day: -5.0%7 days: -10.0%30 days: -17.5%
Close on the filing date to close N calendar days later (from $2.00). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.